Five years ago, the CEO of one of the largest pain clinic companies in the Southeast was sentenced to more than three years in prison after being convicted in a $4 million illegal kickback scheme. But after just four months behind bars, John Estin Davis walked free. President Donald Trump commuted Davis’ sentence in the…
When epidemiologist Sophia Newcomer tries to evaluate how well Montana might be able to ward off the measles outbreak spreading across the U.S., she doesn’t have much data to work with. A federal state-by-state survey last year showed that just over 86% of Montana’s 2-year-olds had recently received the measles, mumps, and rubella immunization. That…
This is not just about today’s older adults — it’s about the next 50 years. If we design a smarter, more sustainable system now, we will all benefit when our time comes. The post America’s Aging Crossroads: Will We Rise to the Challenge or Fall Behind? appeared first on MedCity News.
March has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, providers like Providence and Geisinger have appointed new C-suite leaders, and companies like Blue Shield of California and Evernorth have undergone CEO exits. There were also layoffs at organizations including HHS, Blue Cross of Idaho and the University…
A new poll has industry leaders warning that tariffs will disrupt U.S. healthcare costs and supply chain stability
Talkspace introduced Talkcast on Monday, an AI-powered feature that allows therapists to generate personalized podcast episodes for clients. The post Talkspace Introduces AI-Powered Personalized Podcasts appeared first on MedCity News.
A pioneering program is improving patient outcomes in and outside hospitals
Baker Tilly’s David Hickey says that with health systems under financial pressure, the use of ‘digital workers’ is going to make more sense moving forward
Goal is to create a ‘unified voice to shape healthcare policies, ensuring that telehealth and digital therapeutics remain integral components of the U.S. healthcare system’
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertex’s entry into type 1 diabetes. The post Vertex Cell Therapy Misses in…